NO980957L - Cellesykluskontrollpunktgener - Google Patents

Cellesykluskontrollpunktgener

Info

Publication number
NO980957L
NO980957L NO980957A NO980957A NO980957L NO 980957 L NO980957 L NO 980957L NO 980957 A NO980957 A NO 980957A NO 980957 A NO980957 A NO 980957A NO 980957 L NO980957 L NO 980957L
Authority
NO
Norway
Prior art keywords
cell cycle
cycle checkpoint
checkpoint genes
genes
cell
Prior art date
Application number
NO980957A
Other languages
English (en)
Other versions
NO980957D0 (no
Inventor
Antony Michael Carr
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of NO980957D0 publication Critical patent/NO980957D0/no
Publication of NO980957L publication Critical patent/NO980957L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO980957A 1995-09-06 1998-03-05 Cellesykluskontrollpunktgener NO980957L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9518220.0A GB9518220D0 (en) 1995-09-06 1995-09-06 Checkpoint gene
CZ1998656A CZ292808B6 (cs) 1995-09-06 1996-09-06 ATR polypeptid, polynukleotid, který jej kóduje, způsoby jejich detekce, vektor a protilátka
PCT/GB1996/002197 WO1997009433A1 (en) 1995-09-06 1996-09-06 Cell-cycle checkpoint genes

Publications (2)

Publication Number Publication Date
NO980957D0 NO980957D0 (no) 1998-03-05
NO980957L true NO980957L (no) 1998-05-05

Family

ID=25746866

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980957A NO980957L (no) 1995-09-06 1998-03-05 Cellesykluskontrollpunktgener

Country Status (13)

Country Link
EP (1) EP0856058B1 (no)
JP (1) JPH11511984A (no)
CN (1) CN1201492A (no)
AU (1) AU730220B2 (no)
BR (1) BR9610168A (no)
CA (1) CA2231190A1 (no)
CZ (1) CZ292808B6 (no)
GB (1) GB9518220D0 (no)
IL (1) IL123553A0 (no)
NO (1) NO980957L (no)
PL (1) PL325427A1 (no)
SK (1) SK30298A3 (no)
WO (1) WO1997009433A1 (no)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018323A2 (en) * 1995-11-16 1997-05-22 Icos Corporation Cell-cycle checkpoint phosphatidylinositol- (pik-) related kinases, genes coding therefor and methods for assaying and modulating enzymatic activity
GB9718952D0 (en) * 1997-09-05 1997-11-12 Medical Res Council Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods
CA2321224A1 (en) 1998-02-23 1999-08-26 Icos Corporation Phosphodiesterase 10
US6479256B1 (en) 1998-03-04 2002-11-12 Icos Corporation Lectomedin materials and methods
US6071691A (en) * 1998-04-27 2000-06-06 Oregon Health Science University Materials and methods for modulating differentiation
WO2000061724A2 (en) 1999-04-09 2000-10-19 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
US6670167B1 (en) * 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
US6344549B1 (en) 1999-10-14 2002-02-05 Icos Corporation ATR-2 cell cycle checkpoint
CA2388599A1 (en) 1999-10-22 2001-05-03 Pharmacia & Upjohn Company Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
US6632621B1 (en) 1999-11-24 2003-10-14 Pharmacia & Upjohn Company G protein-coupled receptor-like receptors and modulators thereof
US6498026B2 (en) 2000-02-25 2002-12-24 Hercules Incorporated Variant galactose oxidase, nucleic acid encoding same, and methods of using same
AU2001274894A1 (en) 2000-05-22 2001-12-03 Pharmacia And Upjohn Company Novel matrix metalloproteinases
US6686449B2 (en) 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
AU2001271839A1 (en) 2000-07-05 2002-01-14 Pharmacia And Upjohn Company Human ion channels
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7098007B2 (en) 2001-08-22 2006-08-29 California Institute Of Technology Cloning and functional assays of Xenopus ATR
WO2003068929A2 (en) * 2002-02-13 2003-08-21 University Of Rochester Methods of inhibiting hiv-1 vpr activity and hiv-1 infectivity using atr or rad17 inhibitors
EP2246363A1 (en) 2002-11-15 2010-11-03 Novartis Vaccines and Diagnostics, Inc. Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
WO2005116069A2 (en) 2004-04-14 2005-12-08 Monell Chemical Senses Center Taste receptors of the t1r family from domestic dog
EP2657251B1 (en) 2004-05-24 2018-03-21 The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services Live, oral vaccine for protection against Shigella dysenteriae serotype 1
US20060134698A1 (en) 2004-12-20 2006-06-22 Evanston Northwestern Healthcare Research Institute Methods for treating cardiac disease by modifying an N-terminal domain of troponin I
ES2460517T3 (es) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
EP2705854A1 (en) 2006-01-05 2014-03-12 Novartis AG Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
KR101571027B1 (ko) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
WO2009047567A1 (en) * 2007-10-10 2009-04-16 University Of Sheffield Assay for identifying agents which inhibit the atr and/or dna-pk pathways
CN102099377A (zh) 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
EP3281955A1 (en) 2008-10-02 2018-02-14 Aptevo Research and Development LLC Cd86 antagonist multi-target binding proteins
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
DK2519543T3 (en) 2009-12-29 2016-09-26 Emergent Product Dev Seattle HETERODIMER BINDING PROTEINS AND USE THEREOF
RU2447899C2 (ru) 2010-05-27 2012-04-20 Михаил Валентинович Филатов Композиция для лечения гепатита с и способ лечения гепатита с
IN2015DN00919A (no) 2012-07-13 2015-06-12 Calysta Inc
AU2013342143B2 (en) 2012-11-09 2017-08-10 Calysta, Inc. Compositions and methods for biological production of fatty acid derivatives
EP3011017B1 (en) 2013-06-18 2019-09-11 Calysta, Inc. Compositions and methods for biological production of lactate from c1 compounds using lactate dehydrogenase transformants
JP6543626B2 (ja) 2013-07-29 2019-07-10 ブルーバード バイオ， インコーポレイテッド 多部分シグナル伝達タンパク質およびその使用
WO2015103497A1 (en) 2014-01-02 2015-07-09 Trelys, Inc. Compositions and methods for biological production of amino acids in hydrogenotrophic microorganisms
WO2015109257A1 (en) 2014-01-16 2015-07-23 Calysta, Inc. Carbohydrate-enriched recombinant microorganisms
WO2015120334A2 (en) 2014-02-07 2015-08-13 Effector Therapeutics, Inc. Compositions and methods for treating neurological disorders
JP2017510552A (ja) 2014-02-07 2017-04-13 イーフェクター セラピューティクス， インコーポレイテッド 線維性疾患を治療するための方法
AU2015231461B2 (en) 2014-03-17 2021-09-09 Tapimmune Inc. Nucleic acid molecule vaccine compositions and uses thereof
RU2016145054A (ru) 2014-05-15 2018-06-20 Калиста, Инк. Способы биологического получения соединений с очень длинной углеродной цепью
CA2956545A1 (en) 2014-08-04 2016-02-11 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
EP3212223B1 (en) 2014-10-27 2021-08-18 Fred Hutchinson Cancer Research Center Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy
EP3292208B1 (en) 2015-05-06 2020-08-19 Trelys, Inc. Compositions and methods for biological production of methionine
WO2016187486A1 (en) 2015-05-19 2016-11-24 Fred Hutchinson Cancer Research Center Biomarkers and uses thereof for selecting pancreas cancer intervention
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2017112944A1 (en) 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
US20170191136A1 (en) 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
EP3402878A1 (en) 2016-01-11 2018-11-21 Zoetis Services LLC Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
WO2017192924A1 (en) 2016-05-04 2017-11-09 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
EP3452514A1 (en) 2016-05-06 2019-03-13 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for mart-1
MX2019003176A (es) 2016-09-23 2019-07-04 Hutchinson Fred Cancer Res Receptores de linfocitos t (tcr) especificos del antigeno menor de histocompatibilidad (h) ah-1 y sus usos.
RU2019112860A (ru) 2016-09-27 2020-10-30 Серо Терапьютикс, Инк. Молекулы химерных интернализационных рецепторов
AU2017356322B2 (en) 2016-11-14 2023-09-21 Fred Hutchinson Cancer Center High affinity merkel cell polyomavirus T antigen-specific TCRs and uses thereof
JP7129978B2 (ja) 2016-12-14 2022-09-02 ゾエティス・サービシーズ・エルエルシー 豚繁殖・呼吸障害症候群（ｐｒｒｓ）ウイルスの欧州株に対抗する離乳前の効果的なワクチン接種
EP3580568A1 (en) 2017-02-09 2019-12-18 Fred Hutchinson Cancer Research Center Biomarkers and uses thereof for selecting immunotherapy intervention
SG11201908527SA (en) 2017-03-15 2019-10-30 Hutchinson Fred Cancer Res High affinity mage-a1-specific tcrs and uses thereof
US10780119B2 (en) 2017-05-24 2020-09-22 Effector Therapeutics Inc. Methods and compositions for cellular immunotherapy
WO2019016402A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO
WO2019055862A1 (en) 2017-09-14 2019-03-21 Fred Hutchinson Cancer Research Center HIGH AFFINITY T CELL RECEPTORS AND USES THEREOF
CA3073421A1 (en) 2017-09-26 2019-04-04 Daniel Mark COREY Chimeric engulfment receptor molecules and methods of use
WO2019109047A1 (en) 2017-12-01 2019-06-06 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
EP4295915A3 (en) 2017-12-20 2024-05-22 Harbour Biomed (Shanghai) Co., Ltd Antibodies binding ctla-4 and uses thereof
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
BR112020016330A8 (pt) 2018-02-12 2023-04-18 Hutchinson Fred Cancer Res Receptores de células t específicas a ciclina a1 e usos dos mesmos
CN112041335A (zh) 2018-02-26 2020-12-04 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的组合物和方法
MX2020010241A (es) 2018-03-28 2020-10-16 Cero Therapeutics Inc Composiciones de inmunoterapia celular y usos de las mismas.
WO2019191339A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
EP3774864A1 (en) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
EP3774906A1 (en) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
WO2019232479A2 (en) 2018-06-01 2019-12-05 Fred Hutchinson Cancer Research Center Biomarkers, uses thereof for selecting immunotherapy intervention, and immunotherapy methods
WO2020139974A1 (en) 2018-12-27 2020-07-02 Calysta, Inc. Glycogen-null methanotrophs and uses thereof
WO2020172332A1 (en) 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
BR112021017703A8 (pt) 2019-03-11 2023-04-18 Hutchinson Fred Cancer Res Receptores de células t wt1 de alta avidez e usos dos mesmos
CN114555790A (zh) 2019-08-20 2022-05-27 弗雷德哈钦森癌症研究中心 Wt-1特异性t细胞免疫疗法
WO2021067875A1 (en) 2019-10-03 2021-04-08 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
US20230151102A1 (en) 2020-01-13 2023-05-18 Aptevo Research And Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
MX2022008654A (es) 2020-01-13 2022-08-18 Aptevo Res & Development Llc Formulaciones para productos terapeuticos proteicos.
US11376320B2 (en) 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2
WO2022036287A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Anti-cd72 chimeric receptors and uses thereof
WO2022036265A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Chimeric tim receptors and uses thereof
WO2022036285A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
JP2023542528A (ja) 2020-09-24 2023-10-10 フレッド ハッチンソン キャンサー センター Ｓｏｘ２抗原を標的とする免疫療法
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
TW202214294A (zh) 2020-09-30 2022-04-16 美商碩騰服務公司 具有ｈｙａＣ及ｎａｎＰ缺失之新穎多殺性巴斯德氏菌株及疫苗
TW202222841A (zh) 2020-10-06 2022-06-16 福瑞德哈金森腫瘤研究中心 用於治療表現mage-a1之疾病的組成物及方法
EP4298114A1 (en) 2021-02-26 2024-01-03 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
CN115216451A (zh) 2021-04-16 2022-10-21 硕腾服务有限责任公司 伪狂犬病病毒疫苗
JP2024519964A (ja) 2021-05-21 2024-05-21 アプティーボ リサーチ アンド デベロップメント エルエルシー タンパク質治療薬のための投薬レジメン
EP4376874A1 (en) 2021-07-28 2024-06-05 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018323A2 (en) * 1995-11-16 1997-05-22 Icos Corporation Cell-cycle checkpoint phosphatidylinositol- (pik-) related kinases, genes coding therefor and methods for assaying and modulating enzymatic activity

Also Published As

Publication number Publication date
AU6884696A (en) 1997-03-27
JPH11511984A (ja) 1999-10-19
SK30298A3 (en) 2000-04-10
GB9518220D0 (en) 1995-11-08
PL325427A1 (en) 1998-07-20
BR9610168A (pt) 1998-08-11
CA2231190A1 (en) 1997-03-13
NO980957D0 (no) 1998-03-05
IL123553A0 (en) 1998-10-30
EP0856058B1 (en) 2006-07-26
AU730220B2 (en) 2001-03-01
WO1997009433A1 (en) 1997-03-13
CZ65698A3 (cs) 2000-01-12
CZ292808B6 (cs) 2003-12-17
CN1201492A (zh) 1998-12-09
EP0856058A1 (en) 1998-08-05

Similar Documents

Publication Publication Date Title
NO980957L (no) Cellesykluskontrollpunktgener
NO953680D0 (no) Cellesyklusenzymer
DE59605850D1 (de) Lithium-ionen-zelle
DE69634735D1 (de) Brennstoffzelle
ATE212819T1 (de) Wärmezellen
DE69600381T2 (de) Redox Batterie
DE69603416T2 (de) Elektrochemischer Immunobiosensor
DE69616315D1 (de) Energiespeicher
FR2734058B1 (fr) Amperemetre
BR9607041A (pt) Célula eletroquímica primário
DE69522435T2 (de) Fahrradtrainingsgerät
DE69606428D1 (de) Semigeflutete bleiakkumulatorenzelle
DE59602409D1 (de) Elektrolytzelle
DE69617382D1 (de) Stromspeicherzelle
DE69619908D1 (de) Aufladevorrichtung
DE69620144T2 (de) Stromspeicherzelle
DE69617383D1 (de) Stromspeicherzelle
DE29506494U1 (de) Druckmeßdose
FI961467A0 (fi) Sähkökemiallinen menetelmä
KR970019801U (ko) 배터리 케이스
KR960035948U (ko) 집란장치
DE69600922D1 (de) FlÜGELZELLENMASCHINE
DE59510311D1 (de) Kraftaufnehmer
DE29505572U1 (de) Meßzelle
DE29506247U1 (de) Solarzellenrahmen